Side effects of beta adrenergic antagonists and antianginal drugs
Lindsey M. SteverA. N. AliLauren B. ChambersChristopher J. DemitraszekKatelyn E. JimisonSheena A. MurrayKelsey Tuttle
2
Citation
63
Reference
10
Related Paper
Citation Trend
A d m in is tr a ti o n o f n if ed ip in e w it h '' g ra p ef ru it '' '' ju ic e' ' is tob ea v o id edA D V IC O R 1 (Ko s) (n ia ci nex te n d ed -r el ea se / lo v a st a ti nta b le ts ) N o v emb er2 0 0 3la b el in gW a rn in g sT h e ri sko f m y o p a th y a p p ea rs tob e in cr ea se d b y h ig h le v el s o fH M G -C o A re d u ct a se in h ib it o rya ct iv it y in p la sma . L o v a st a ti n ism et a b o li ze d b y th e C Y P is o fo rm3 A 4 . C er ta ind ru g s, th a t sh a reth is m et a b o li c p a th w a y ca n ra is e th e p la sma le v el s o f lo v a st a ti na n d m a y in cr ea seth e ri sko f m y o p a th y . T h es e in cl u d ecy cl o sp o ri n e, it ra co n a zo le , k et o co n a zo le a n d o th era n ti fu n g a la zo le s, th e m a cr o li d e a n ti b io ti cser y th ro m y ci n a n dcl a ri th ro m y ci n , H IVp ro te a sein h ib it o rs , th e a n ti d ep re ss a n tn ef a zo d o n e, o r la rg e q u a n ti ti eso f '' g ra p ef ru it '' '' ju ic e' ' (g re a te rth a n 1 q u a rt d a il y )P re ca u ti o n sS h o u ldn o t b e a d m in is te re d w it h '' g ra p ef ru it '' '' ju ic e' 'C li n ic a l P h a rma co lo g y :P h a rma co k in et ic s a b so rp ti o nL o v a st a ti n a b so rp ti o n a p p ea rs tob e in cr ea se d b y a t le a st 3 0 %b y'' g ra p ef ru it '' '' ju ic e' '; h o w ev er , th e ef fe ct is d ep en d en t o n th ea m o u n t o f '' g ra p ef ru it '' '' ju ic e' ' co n su m eda n d th e in te rv a lb et w ee n '' g ra p ef ru it '' '' ju ic e' ' a n d lo v a st a ti n in g es ti o nM E V A C O R 1 (Mer ck )(L o v a st a ti n ) ta b le ts Ju n e 2 0 0 2la b el in gC li n ic a l P h a rma co lo g y :A b so rp ti o nL o v a st a ti n is a su b st ra te fo r C Y P 3 A 4 (s ee'' P re ca u ti o n s: D ru gIn te ra ct io n s' ') . '' G ra p ef ru it '' '' ju ic e' ' co n ta in s o n e o r m o reco m p o n en ts th a t in h ib it C Y P 3 A 4 a n d ca n in cr ea seth e p la sma co n ce n tr a ti o n s o f d ru g s m et a b o li ze d b y C Y P 3 A 4 . Ino n e st u d y(1 ), 1 0 su b je ct s co n su m ed2 0 0 m L o f d o u b le -s tr en g th'' g ra p ef ru it '' '' ju ic e' ' (o n e ca n o f fr o ze n co n ce n tr a te d il u te d w it ho n e ra th erth a n th re e ca n s o f w a te r) th re e ti m esd a il y fo r tw od a y s a n d a n a d d it io n a l 2 0 0 m L d o u b le -s tr en g th'' g ra p ef ru it '''' ju ic e' ' to g et h erw it h a n d 3 0 a n d 9 0 m info ll o w in g a si n g le d o seo f 8 0 m g lo v a st a ti n o n th e th ir d d a y . T h is re g im eno f'' g ra p ef ru it '' '' ju ic e' ' re su lt edin m ea n in cr ea se s inth eco n ce n tr a ti o n o f lo v a st a ti n a n d it s b et a -h y d ro x y a ci d m et a b o li te(C o n ti n u ed )T able 4L a b el in g E x a m p le s o f D ru g – G ra p ef ru it Ju ic e In te ra ct io n s (C o n ti n u ed )D ru g n a m eL a b el in g se ct io nL a b el in g(a s m ea su re d b y th e a re a u n d erth e co n ce n tr a ti o n -t im e cu rv e) o f1 5 -f o lda n d fi v ef o ldre sp ec ti v el y (a s m ea su re d u si n g a ch emic a la ss a y — li q u id ch ro m a to g ra p h y / ta n d emm a ss sp ec tr o m et ry ). Ina se co n d st u d y , 1 5 su b je ct s co n su m edo n e 8 o z g la ss o f si n g le -st re n g th'' g ra p ef ru it '' '' ju ic e' ' (o n e ca n o f fr o ze n co n ce n tr a ted il u te d w it h th re e ca n s o f w a te r) w it h b re a k fa st fo r th re eco n se cu ti v e d a y s a n d a si n g le d o seo f 4 0 m g lo v a st a ti n inth eev en in g o f th e th ir d d a y . T h is re g im eno f '' g ra p ef ru it '' '' ju ic e' 're su lt edin a m ea n in cr ea sein th e p la sma co n ce n tr a ti o n (a sm ea su re d b y th e a re a u n d erth e co n ce n tr a ti o n -t im e cu rv e) o fa ct iv e a n d to ta l H M G -C o A re d u ct a se in h ib it o rya ct iv it y [u si n g av a li d a te d en zy m e in h ib it io n a ss a y d if fe re n t fr o m th a t u se d in th efi rs t st u d y , b o thb ef o re(f o r a ct iv e in h ib it o rs ) a n d a ft er(f o r to ta lin h ib it o rs ) b a seh y d ro ly si s] o f 1 .3 4 -f o lda n d 1 .3 6 -f o ld ,re sp ec ti v el y , a n d o f lo v a st a ti n a n d it s (b et a )- h y d ro x y a ci dm et a b o li te (mea su re d u si n g a ch emic a l a ss a y — li q u idch ro m a to g ra p h y / ta n d emm a ss sp ec tr o m et ry ) o f 1 .9 4 -f o lda n d1 .5 7 -f o ld , re sp ec ti v el y . T h e ef fe ct o f a m o u n ts o f '' g ra p ef ru it '''' ju ic e' ' b et w ee n th o seu se d inth es e tw o st u d ie s o n lo v a st a ti np h a rma co k in et ic s h a s n o t b ee n st u d ie dW a rn in g sT h e ri sko f m y o p a th y / rh a b d o m y o ly si sis in cr ea se d b y co n co m it a n t u seo f lo v a st a ti n w it h th e fo ll o w in g :P o te n t in h ib it o rs o f C Y P 3 A 4 : C y cl o sp o ri n e, it ra co n a zo le ,k et o co n a zo le , er y th ro m y ci n , cl a ri th ro m y ci n , H IVp ro te a sein h ib it o rs , n ef a zo d o n e, o r la rg e q u a n ti ti eso f '' g ra p ef ru it '''' ju ic e' ' (g re a te r th a n 1 q u a rt d a il y ), p a rt ic u la rl y w it h h ig h erd o se s o f lo v a st a ti n (s eeb el o w : '' C li n ic a l P h a rma co lo g y :P h a rma co k in et ic s; P re ca u ti o n s: D ru g In te ra ct io n s, C Y P 3 A 4In te ra ct io n s' ')B IL T R IC IDE 1 (B a y er )(p ra zi q u a n te l) ta b le ts A u g u st2 0 0 4 la b el in gC li n ic a l P h a rma co lo g y'' G ra p ef ru it '' '' ju ic e' ' w a s re p o rt edto p ro d u cea 1 .6 -f o ld in cr ea se inth e C m a x a n d a 1 .9 -f o ldin cr ea sein th e A U C o f p ra zi q u a n te lD ru g – d ru g in te ra ct io n sH o w ev er , th e ef fe cto f th is ex p o su rein cr ea seo n th e th er a p eu ti cef fe ct a n d sa fe tyo f p ra zi q u a n te l h a s n o t b ee n sy st ema ti ca ll yev a lu a te dC E N E S T IN 1 (Du ra m ed )(s y n th et ic co n ju g a te des tr o g en s, A ) F eb ru a ry2 0 0 4la b el in gC li n ic a l P h a rma co lo g y : D ru g –d ru g in te ra ct io n sIn h ib it o rs o f C Y P 3 A 4 su cha s er y th ro m y ci n , cl a ri th ro m y ci n ,k et o co n a zo le , it ra co n a zo le , ri to n a v ir a n d '' g ra p ef ru it '' '' ju ic e' 'm a y in cr ea sep la sma co n ce n tr a ti o n s o f es tr o g en s a n d m a y re su ltin si d e ef fe ct scC IAL IS 1 (L il ly IC O S )(t a d a la fi l) N o v emb er2 0 0 3la b el in gP re ca u ti o n s: D ru g – d ru gin te ra ct io n sK et o co n a zo le (4 0 0 m g d a il y ), a se le ct iv e a n d p o te n t in h ib it o r o fC Y P 3 A 4 , in cr ea se d ta d a la fi l 2 0 -mg si n g le -d o seex p o su re(A U C )b y 3 1 2 % . O th erC Y P in h ib it o rs — A lt h o u g h sp ec ifi c in te ra ct io n sh a v e n o t b ee n st u d ie d , o th erC Y P 3 A 4 in h ib it o rs , su cha ser y th ro m y ci n , it ra co n a zo le , a n d '' g ra p ef ru it '' '' ju ic e, '' w o u ldli k el y in cr ea seta d a la fi l ex p o su re .
Cite
Citations (0)
Drug action
Cite
Citations (0)
In this paper,we proposed the concepts of me-too drug,me-better drug and me-new drug according to our understanding of drug RD in China.We described the relations among me-too,me-better and me-new drugs,and the relation between innovative degree and economic returns during drug RD as well as the route for drug RD in China.
Cite
Citations (0)
Cite
Citations (0)
Cite
Citations (1)
Drug-drug interactions in diabetic patients could be serious, even life threatening. Possible manifestation of hypo/hyperglycemia as a consequence of drug-drug interactions are often wrong interpreted as a nonadherence to the diabetic diet or polymorbidity of the patient. Drug-drug interactions are not taken into account. The risk of drug-drug interactions is exponentially increasing with the number of taken drugs. In the group of diabetic patients is good to prevent the combinations of drugs, which can lead to drug-drug interactions and use alternative therapy with lower potential of drug-drug interactions. In this paper we present the possibilities of clinical pharmacist from the Department of clinical pharmacology to prevent and solve the drug-drug interactions in diabetic patients.
Pharmacotherapy
Cite
Citations (1)
Side chain
Demand side
Client-side
Cite
Citations (0)
Cite
Citations (0)